Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
Open Access
- 1 January 2019
- journal article
- review article
- Published by OAE Publishing Inc. in Cancer Drug Resistance
- Vol. 2 (2) , 271-296
Abstract
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.Keywords
This publication has 100 references indexed in Scilit:
- Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkersCancer Medicine, 2012
- Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistanceDrug Resistance Updates, 2012
- XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinaseDNA Repair, 2011
- Translational application of epigenetic alterations: Ovarian cancer as a modelFEBS Letters, 2011
- Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancerCancer, 2010
- A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancerCancer, 2010
- Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancerInternational Journal of Cancer, 2009
- Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancerInternational Journal of Cancer, 2009
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2007
- The language of covalent histone modificationsNature, 2000